Institut du Cancer d’Avignon (<\/a><\/span>Institut Sainte Catherine), les laboratoires Bioaxiome, et en particulier le Dr Emmanuel Goffart,\u00a0 participent activement \u00e0 cette \u00e9tude.<\/p>\n <\/p>\n
🦠Elle consiste \u00e0 d\u00e9terminer le statut immunitaire post-vaccinal Sars-Cov2 chez des patients atteints de pathologies onco-h\u00e9matologiques immuno-suppressives<\/strong>, dans le but de d\u00e9finir une politique de rappel vaccinal adapt\u00e9e \u00e0 leur \u00e9tat immunitaire.<\/p>\n <\/p>\n
🩸Ce travail a \u00e9t\u00e9 reconnu par l’American Society of Haematology<\/strong>\u00a0 : un poster a \u00e9t\u00e9 pr\u00e9sent\u00e9 au congr\u00e8s d’Atlanta le 11\/12\/21 et dans le suppl\u00e9ment de \u00ab\u00a0Blood\u00a0\u00bb, issu du congr\u00e8s de l’ASH.<\/p>\n <\/p>\n
🔹 Publication Number: 1879<\/i><\/p>\n
🔹 Submission ID: 154539<\/i><\/p>\n
🔹 TITLE: BNT162b2 mRNA COVID-19 Vaccination (BNTCV) in Patients (Pts) Having Hematological Malignancies (HM): Early tolerance with telemedicine application connecting and antibody anti-Spike IgG response (AcAS)<\/i><\/p>\n
<\/p>\n
F\u00e9licitations \u00e0 toutes les \u00e9quipes ayant travaill\u00e9 sur cette publication 👏<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"Bioaxiome participe activement \u00e0 une \u00e9tude sur les vaccins Covid chez les patients atteints de pathologies sp\u00e9cifiques Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":21,"featured_media":9861,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_links_to":"","_links_to_target":""},"categories":[1,197],"tags":[],"acf":[],"yoast_head":"\nLes vaccins Covid chez les patients atteints de pathologies sp\u00e9cifiques - Groupe Inovie<\/title>\n<meta name=\"description\" content=\"Bioaxiome participe activement \u00e0 une \u00e9tude sur les vaccins Covid chez les patients atteints de pathologies sp\u00e9cifiques\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/groupeinovie.net\/2022\/01\/10\/etude-sur-les-vaccins-covid-chez-les-patients-atteints-de-pathologies-specifiques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Les vaccins Covid chez les patients atteints de pathologies sp\u00e9cifiques - Groupe Inovie\" \/>\n<meta property=\"og:description\" content=\"Bioaxiome participe activement \u00e0 une \u00e9tude sur les vaccins Covid chez les patients atteints de pathologies sp\u00e9cifiques\" \/>\n<meta property=\"og:url\" content=\"https:\/\/groupeinovie.net\/2022\/01\/10\/etude-sur-les-vaccins-covid-chez-les-patients-atteints-de-pathologies-specifiques\/\" \/>\n<meta property=\"og:site_name\" content=\"Groupe Inovie\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-10T09:26:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-21T09:33:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/groupeinovie.net\/wp-content\/uploads\/sites\/55\/2022\/01\/Capture-de\u0301cran-2022-01-21-a\u0300-10.28.45-1024x578.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"578\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Labosud Groupe Communication\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Labosud Groupe Communication\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/groupeinovie.net\/2022\/01\/10\/etude-sur-les-vaccins-covid-chez-les-patients-atteints-de-pathologies-specifiques\/\",\"url\":\"https:\/\/groupeinovie.net\/2022\/01\/10\/etude-sur-les-vaccins-covid-chez-les-patients-atteints-de-pathologies-specifiques\/\",\"name\":\"Les vaccins Covid chez les patients atteints de pathologies sp\u00e9cifiques - Groupe Inovie\",\"isPartOf\":{\"@id\":\"https:\/\/groupeinovie.net\/#website\"},\"datePublished\":\"2022-01-10T09:26:21+00:00\",\"dateModified\":\"2022-01-21T09:33:49+00:00\",\"author\":{\"@id\":\"https:\/\/groupeinovie.net\/#\/schema\/person\/49006d15238e00543cff98db08aaf206\"},\"description\":\"Bioaxiome participe activement \u00e0 une \u00e9tude sur les vaccins Covid chez les patients atteints de pathologies sp\u00e9cifiques\",\"breadcrumb\":{\"@id\":\"https:\/\/groupeinovie.net\/2022\/01\/10\/etude-sur-les-vaccins-covid-chez-les-patients-atteints-de-pathologies-specifiques\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/groupeinovie.net\/2022\/01\/10\/etude-sur-les-vaccins-covid-chez-les-patients-atteints-de-pathologies-specifiques\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/groupeinovie.net\/2022\/01\/10\/etude-sur-les-vaccins-covid-chez-les-patients-atteints-de-pathologies-specifiques\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/groupeinovie.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Les vaccins Covid chez les patients atteints de pathologies sp\u00e9cifiques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/groupeinovie.net\/#website\",\"url\":\"https:\/\/groupeinovie.net\/\",\"name\":\"Groupe Inovie\",\"description\":\"Premier Groupe Lib\u00e9ral de France\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/groupeinovie.net\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/groupeinovie.net\/#\/schema\/person\/49006d15238e00543cff98db08aaf206\",\"name\":\"Labosud Groupe Communication\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/groupeinovie.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/41dce42773c69f757749bb4e4d657217?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/41dce42773c69f757749bb4e4d657217?s=96&d=mm&r=g\",\"caption\":\"Labosud Groupe Communication\"},\"sameAs\":[\"http:\/\/labosud.com\"],\"url\":\"https:\/\/groupeinovie.net\/author\/labosud-groupe\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Les vaccins Covid chez les patients atteints de pathologies sp\u00e9cifiques - Groupe Inovie","description":"Bioaxiome participe activement \u00e0 une \u00e9tude sur les vaccins Covid chez les patients atteints de pathologies sp\u00e9cifiques","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/groupeinovie.net\/2022\/01\/10\/etude-sur-les-vaccins-covid-chez-les-patients-atteints-de-pathologies-specifiques\/","og_locale":"fr_FR","og_type":"article","og_title":"Les vaccins Covid chez les patients atteints de pathologies sp\u00e9cifiques - Groupe Inovie","og_description":"Bioaxiome participe activement \u00e0 une \u00e9tude sur les vaccins Covid chez les patients atteints de pathologies sp\u00e9cifiques","og_url":"https:\/\/groupeinovie.net\/2022\/01\/10\/etude-sur-les-vaccins-covid-chez-les-patients-atteints-de-pathologies-specifiques\/","og_site_name":"Groupe Inovie","article_published_time":"2022-01-10T09:26:21+00:00","article_modified_time":"2022-01-21T09:33:49+00:00","og_image":[{"width":1024,"height":578,"url":"https:\/\/groupeinovie.net\/wp-content\/uploads\/sites\/55\/2022\/01\/Capture-de\u0301cran-2022-01-21-a\u0300-10.28.45-1024x578.png","type":"image\/png"}],"author":"Labosud Groupe Communication","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Labosud Groupe Communication","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/groupeinovie.net\/2022\/01\/10\/etude-sur-les-vaccins-covid-chez-les-patients-atteints-de-pathologies-specifiques\/","url":"https:\/\/groupeinovie.net\/2022\/01\/10\/etude-sur-les-vaccins-covid-chez-les-patients-atteints-de-pathologies-specifiques\/","name":"Les vaccins Covid chez les patients atteints de pathologies sp\u00e9cifiques - Groupe Inovie","isPartOf":{"@id":"https:\/\/groupeinovie.net\/#website"},"datePublished":"2022-01-10T09:26:21+00:00","dateModified":"2022-01-21T09:33:49+00:00","author":{"@id":"https:\/\/groupeinovie.net\/#\/schema\/person\/49006d15238e00543cff98db08aaf206"},"description":"Bioaxiome participe activement \u00e0 une \u00e9tude sur les vaccins Covid chez les patients atteints de pathologies sp\u00e9cifiques","breadcrumb":{"@id":"https:\/\/groupeinovie.net\/2022\/01\/10\/etude-sur-les-vaccins-covid-chez-les-patients-atteints-de-pathologies-specifiques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/groupeinovie.net\/2022\/01\/10\/etude-sur-les-vaccins-covid-chez-les-patients-atteints-de-pathologies-specifiques\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/groupeinovie.net\/2022\/01\/10\/etude-sur-les-vaccins-covid-chez-les-patients-atteints-de-pathologies-specifiques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/groupeinovie.net\/"},{"@type":"ListItem","position":2,"name":"Les vaccins Covid chez les patients atteints de pathologies sp\u00e9cifiques"}]},{"@type":"WebSite","@id":"https:\/\/groupeinovie.net\/#website","url":"https:\/\/groupeinovie.net\/","name":"Groupe Inovie","description":"Premier Groupe Lib\u00e9ral de France","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/groupeinovie.net\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/groupeinovie.net\/#\/schema\/person\/49006d15238e00543cff98db08aaf206","name":"Labosud Groupe Communication","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/groupeinovie.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/41dce42773c69f757749bb4e4d657217?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41dce42773c69f757749bb4e4d657217?s=96&d=mm&r=g","caption":"Labosud Groupe Communication"},"sameAs":["http:\/\/labosud.com"],"url":"https:\/\/groupeinovie.net\/author\/labosud-groupe\/"}]}},"_links":{"self":[{"href":"https:\/\/groupeinovie.net\/wp-json\/wp\/v2\/posts\/9856"}],"collection":[{"href":"https:\/\/groupeinovie.net\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/groupeinovie.net\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/groupeinovie.net\/wp-json\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/groupeinovie.net\/wp-json\/wp\/v2\/comments?post=9856"}],"version-history":[{"count":0,"href":"https:\/\/groupeinovie.net\/wp-json\/wp\/v2\/posts\/9856\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/groupeinovie.net\/wp-json\/wp\/v2\/media\/9861"}],"wp:attachment":[{"href":"https:\/\/groupeinovie.net\/wp-json\/wp\/v2\/media?parent=9856"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/groupeinovie.net\/wp-json\/wp\/v2\/categories?post=9856"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/groupeinovie.net\/wp-json\/wp\/v2\/tags?post=9856"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}